Targeting respiratory diseases using miRNA inhibitor based nanotherapeutics: Current status and future perspectives

Mehta M 1 , Satija S 2 , Paudel KR 3 , Malyla V 1 , Kannaujiya VK 4 , Chellappan DK 5 Show all authors , Bebawy M 6 , Hansbro PM 3 , Wich PR 7 , Dua K 8

Affiliations 

  • 1 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, Australia; Centre for Inflammation, Centenary Institute, Sydney, NSW, Australia
  • 2 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, Australia; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
  • 3 Centre for Inflammation, Centenary Institute, Sydney, NSW, Australia; School of Life Sciences, University of Technology Sydney, Ultimo, NSW, Australia
  • 4 School of Chemical Engineering, University of New South Wales, Sydney, NSW, Australia
  • 5 Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia
  • 6 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, Australia
  • 7 School of Chemical Engineering, University of New South Wales, Sydney, NSW, Australia; Centre for Nanomedicine, University of New South Wales, Sydney, NSW, Australia
  • 8 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, Australia; Centre for Inflammation, Centenary Institute, Sydney, NSW, Australia; Priority Research Centre for Healthy Lungs, University of Newcastle & Hunter Medical Research Institute, New Lambton Heights, Newcastle, NSW, Australia; School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh, India. Electronic address: [email protected]
Nanomedicine, 2021 01;31:102303.
PMID: 32980549 DOI: 10.1016/j.nano.2020.102303

Abstract

MicroRNAs (miRNAs) play a fundamental role in the developmental and physiological processes that occur in both animals and plants. AntagomiRs are synthetic antagonists of miRNA, which prevent the target mRNA from suppression. Therapeutic approaches that modulate miRNAs have immense potential in the treatment of chronic respiratory disorders. However, the successful delivery of miRNAs/antagomiRs to the lungs remains a major challenge in clinical applications. A range of materials, namely, polymer nanoparticles, lipid nanocapsules and inorganic nanoparticles, has shown promising results for intracellular delivery of miRNA in chronic respiratory disorders. This review discusses the current understanding of miRNA biology, the biological roles of antagomiRs in chronic respiratory disease and the recent advances in the therapeutic utilization of antagomiRs as disease biomarkers. Furthermore our review provides a common platform to debate on the nature of antagomiRs and also addresses the viewpoint on the new generation of delivery systems that target antagomiRs in respiratory diseases.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications